ADRIAMYCIN COMBINATIONS AS SALVAGE THERAPY IN ADVANCED MOPP‐RESISTANT HODGKIN'S DISEASE

Publisher Website
Google Scholar
Abstract
Thirty-one patients with advanced MOPP[nitrogen mustard, vincristine, procarbazine, prednisone]-resistant Hodgkin''s disease were treated with adriamycin, bleomycin, vinca alkaloid and prednisolone (ABVP). Sixteen patients received vinblastine, 7 received vincristine and 8 received VM26 [teniposide]. Of 28 patients evaluable for response, 17 (61%) achieved an objective response with 5 (18%) complete responders. Response was significantly inferior in patients receiving VM26. Patients with a prolonged interval since previous chemotherapy had a greater chance of complete response (P < 0.02) as did those with previous complete response to MOPP therapy (P < 0.05). Response to treatment did not affect overall survival (P = 0.8), although relapse free survival was significantly longer for those achieving complete response (P < 0.01). The regimen produced minimal gastrointestinal toxicity, but significant myelosuppression. ABVP is a well tolerated salvage therapy in advanced MOPP-resistant Hodgkin''s disease.